ArticleInternational journal of general medicine2025
Correlation Between Blood Pressure Variability and Serum Vascular Endothelial Growth Factor Concentration in Patients with Type I Cerebral Small Vessel Disease.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- New perspectives on VEGF signalling in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the relationship between blood pressure variability (BPV) and serum vascular endothelial growth factor (VEGF) levels in patients with type I cerebral small vessel disease (CSVD). Methods: 144 Patients admitted to the Neurology Department of our Hospital between December 2021 and December 2022 were included and categorized into 5 groups according to CSVD burden, which was evaluated based on MRI findings. Group 0-2 were categorized as mild patients, group 3 as moderate patients, group 4 as severe patients. All patients underwent 24-hour ambulatory blood pressure monitoring. Serum samples were collected to measure the concentration of VEGF. The differences of general information, BPV and serum VEGF levels in five groups were compared. Spearman correlation analysis was used to analyze the correlation between total CSVD burden and BPV, as well as total CSVD burden and serum VEGF concentration. Additionally, Pearson correlation analysis was used to explore the correlation between serum VEGF level and BPV. Results: 83 males and 61 females with mean age of (67.5±9.9) years were enrolled. Significant differences were observed in age and hypertension history among the five groups (p<0.001). In both mild and severe groups, 24hSBP, 24hSBP-SD, 24hSBP-CV, 24hSBP-ARV, DSBP, DSBP-SD, DSBP-ARV, 24hDBP, 24hDBP-SD, DDBP, NDBP showed a significant positive correlation with the total CSVD burden scores. The differences in serum VEGF concentration among the five groups were statistically significant (P<0.05), with the lowest in group 4 and the highest in group 3. Serum VEGF concentration showed a significant positive correlation with the total CSVD burden scores in patients with mild to moderate CSVD. Pearson's correlation analysis revealed that serum VEGF concentration was significantly and positively correlated with 24hSBP-SD, 24hSBP- ARV, DSBP-SD, DSBP-ARV, and SBP-wSD. Conclusion: VEGF may be associated with the impact of BPV on CSVD patients, and potentially correlated to delaying disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.